Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BPTF | Q12830 | 1/20 | 0.54 |
| ▸ | DPP4 | P27487 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.43 |
| ▸ | HTR3B | O95264 | 1/20 | 0.43 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.43 |
| ▸ | HTR3A | P46098 | 1/20 | 0.43 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.43 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.42 |
| ▸ | DRD4 | P21917 | 1/20 | 0.42 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.41 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL30182618 | 0.98 | BPTF (0.52) | BPTFDPP4LMNAHTR3EHTR3B | |
| SCHEMBL17304860 | 0.91 | BPTF (0.50) | BPTFDPP4LMNAHTR3EHTR3B | |
| SCHEMBL17294901 | 0.91 | BPTF (0.50) | BPTFDPP4LMNAHTR3EHTR3B | |
| SCHEMBL20858814 | 0.82 | BPTF (0.57) | BPTFDPP4LMNAHTR3EHTR3B | |
| SCHEMBL314421 | 0.82 | NOTUM (0.55) | BPTFDPP4LMNAHTR3EHTR3B | |
| SCHEMBL21628259 | 0.82 | NOTUM (0.55) | BPTFDPP4LMNAHTR3EHTR3B | |
| SCHEMBL8386956 | 0.82 | NOTUM (0.55) | BPTFDPP4LMNAHTR3EHTR3B | |
| SCHEMBL30818891 | 0.81 | BPTF (0.50) | BPTFDPP4LMNAHTR3EHTR3B | |
| SCHEMBL4634871 | 0.81 | BPTF (0.50) | BPTFDPP4LMNAHTR3EHTR3B | |
| Hydrochloric Acid SCHEMBL30775623 | 0.81 | NOTUM (0.53) | BPTFDPP4LMNAHTR3EHTR3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12391663-B2 | Isoindolinone compounds | MONTE ROSA THERAPEUTICS AG (CH) | 2025-08-19 | — | — | US | disclosed |
| US-20250115581-A1 | SUBSTITUTED PIPERIDINES AS CK1A DEGRADERS | MONTE ROSA THERAPEUTICS AG (CH) | 2025-04-10 | — | — | US | disclosed |
| US-20240261274-A1 | TREATMENT OF MYC-DRIVEN CANCERS WITH GSPT1 DEGRADERS | MONTE ROSA THERAPEUTICS AG (CH) | 2024-08-08 | — | — | US | disclosed |
| US-20240083869-A1 | ISOINDOLINONE COMPOUNDS | MONTE ROSA THERAPEUTICS AG (CH) | 2024-03-14 | — | — | US | disclosed |
| US-11912682-B2 | Isoindolinone compounds | MONTE ROSA THERAPEUTICS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| EP-4323350-A1 | ISOINDOLINONE COMPOUNDS | Monte Rosa Therapeutics AG (CH) | 2024-02-21 | — | — | EP | disclosed |
| US-20240051936-A1 | ISOINDOLINONE COMPOUNDS | MONTE ROSA THERAPEUTICS AG (CH) | 2024-02-15 | — | — | US | disclosed |
| CN-115919859-B | Pharmaceutical composition of heteroaryl derivative and application of pharmaceutical composition in medicine | 四川海思科制药有限公司 | 2024-01-05 | — | — | CN | disclosed |
| WO-2023244817-A1 | SUBSTITUTED PIPERIDINES AS CK1A DEGRADERS | MONTE ROSA THERAPEUTICS, INC. (US) | 2023-12-21 | — | — | WO | disclosed |
| CN-117242060-A | Isoindolinone compounds | 蒙特罗萨医疗公司 | 2023-12-15 | — | — | CN | disclosed |
| US-10544102-B2 | Benzazepine dicarboxamide compounds with secondary amide function | HOFFMANN-LA ROCHE INC. (US) | 2020-01-28 | — | — | US | disclosed |
| EP-3464274-A1 | BENZAZEPINE DICARBOXAMIDE COMPOUNDS WITH SECONDARY AMIDE FUNCTION | H. Hoffnabb-La Roche Ag (CH) | 2019-04-10 | — | — | EP | disclosed |
| US-20190077764-A1 | BENZAZEPINE DICARBOXAMIDE COMPOUNDS WITH SECONDARY AMIDE FUNCTION | HOFFMANN-LA ROCHE INC. (US) | 2019-03-14 | — | — | US | disclosed |
| US-20190077764-A1 | BENZAZEPINE DICARBOXAMIDE COMPOUNDS WITH SECONDARY AMIDE FUNCTION | HOFFMANN-LA ROCHE INC. (US) | 2019-03-14 | — | — | US | disclosed |
| CN-109311854-A | Benzazepine diformamide compound with secondary amide functional group | 豪夫迈·罗氏有限公司 | 2019-02-05 | — | — | CN | disclosed |
| CN-109153648-A | Benzazepine diformamide compound with teritary amide functional group | 豪夫迈·罗氏有限公司 | 2019-01-04 | — | — | CN | disclosed |
| WO-2017202703-A1 | BENZAZEPINE DICARBOXAMIDE COMPOUNDS WITH SECONDARY AMIDE FUNCTION | F. HOFFMANN-LA ROCHE AG (CH) | 2017-11-30 | — | — | WO | disclosed |
| WO-2017202703-A1 | BENZAZEPINE DICARBOXAMIDE COMPOUNDS WITH SECONDARY AMIDE FUNCTION | F. HOFFMANN-LA ROCHE AG (CH) | 2017-11-30 | — | — | WO | disclosed |
| EP-1069132-B1 | Bicyclic derivatives of amino-pyrazinones, process of preparation and pharmaceutical compositions comprising them | SERVIER LAB (FR) | 2003-10-01 | — | — | EP | disclosed |
| EP-1069132-A1 | Bicyclic derivatives of amino-pyrazinones, process of preparation and pharmaceutical compositions comprising them | ADIR ET COMPAGNIE (FR) | 2001-01-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190077764-A1 | BENZAZEPINE DICARBOXAMIDE COMPOUNDS WITH SECONDARY AMIDE FUNCTION | TLR1, TLR5, TLR4 | BPTF 1560/4885DPP4 541/4885LMNA 4489/4885 |
| US-10544102-B2 | Benzazepine dicarboxamide compounds with secondary amide function | TLR1, TLR5, TLR4 | BPTF 1560/4885DPP4 541/4885LMNA 4489/4885 |
| US-12391663-B2 | Isoindolinone compounds | CYP4F2, AOC2, AOC3 | BPTF 517/4885DPP4 3917/4885LMNA 1164/4885 |
| US-20240083869-A1 | ISOINDOLINONE COMPOUNDS | CYP4F2, AOC2, AOC3 | BPTF 517/4885DPP4 3917/4885LMNA 1164/4885 |
| US-20250115581-A1 | SUBSTITUTED PIPERIDINES AS CK1A DEGRADERS | CKS1B, CSNK1A1, CKS2 | BPTF 2864/4885DPP4 929/4885LMNA 2078/4885 |
| US-20240051936-A1 | ISOINDOLINONE COMPOUNDS | CRBN, CDR2, POU2F2 | BPTF 481/4885DPP4 4609/4885LMNA 434/4885 |
| US-11912682-B2 | Isoindolinone compounds | CYP4F2, AOC2, AOC3 | BPTF 517/4885DPP4 3917/4885LMNA 1164/4885 |
| US-20240261274-A1 | TREATMENT OF MYC-DRIVEN CANCERS WITH GSPT1 DEGRADERS | MYC, MYCBP, GSPT1 | BPTF 1874/4885DPP4 1434/4885LMNA 3911/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.